Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells
- PMID: 6178756
- PMCID: PMC371243
- DOI: 10.1172/jci110624
Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells
Abstract
To determine the pharmacologic importance of methotrexate (MTX) polyglutamates, we examined the formation, retention, and effect of these metabolites in cultured human breast cancer cells. Two cell lines (MCF-7 and ZR-75-B) converted the drug to gamma-polyglutamate derivatives in a dose- and time-dependent reaction. After 24-h incubations with 2 muM MTX, polyglutamates of two to five amino acids in length accounted for 55.4% (51.9 nmol/g) of intracellular drug in the MCF-7 cells and 87.6% (62.4 nmol/g) of drug in ZR-75-B cells. In contrast, MDA-231 cells showed lesser accumulation of MTX, and only 32% (4.06 nmol/g) of the intracellular drug was in the form of polyglutamates, a difference that could only partially be explained by decreased ability of these cells to take up free drug from the medium. When MCF-7 and ZR-75-B cells containing polyglutamates were transferred to drug-free medium for 24 h, 22 and 51% of the total intracellular drug were, respectively, retained in each cell line. The loss of intracellular drug was primarily accounted for by disappearance of parent compound and polyglutamates containing 1-3 additional glutamyl residues. The rates of disappearance from cells decreased with increasing glutamyl chain length. All of the 4-NH(2)-10-CH(3)-PteGlu(5) and 47 and 38% of the 4-NH(2)-10-CH(3)-PteGlu(4) remained in the MCF-7 and ZR-75-B cells, respectively, and could be identified in the cytosol after 24 h in drug-free medium. The retention of MTX polyglutamates in these two cell lines in excess of dihydrofolate reductase binding capacity led to prolonged inhibition of thymidylate synthesis and loss of cell viability after removal of extracellular MTX. After 24-h incubation with 2 muM MTX and an additional 24 h in drug-free medium, [(3)H]deoxyuridine incorporation was still inhibited to 30% of control in the MCF-7 cells and 34.7% of control in ZR-75-B cells; this persistent inhibition was associated with a 30% reduction in cell numbers in each cell line during the 24-h period in drug-free medium. In contrast, [(3)H]deoxyuridine incorporation and cell growth quickly recovered to normal in the MDA-231 cells following removal of 2 muM MTX from the medium after a 24-h incubation. Prolonged inhibition of both thymidylate synthesis and cell growth was observed in this cell line in drug-free medium only after a 24-h incubation with 10 muM MTX, a condition that leads to the synthesis of 11.3 nmol/g of MTX polyglutamates. These studies demonstrate that polyglutamate formation allows a prolonged retention of drug in a noneffluxable form and prolonged inhibition of both thymidylate synthesis and cell growth following removal of extracellular drug.
Similar articles
-
Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.J Clin Invest. 1983 Sep;72(3):773-8. doi: 10.1172/JCI111048. J Clin Invest. 1983. PMID: 6193143 Free PMC article.
-
Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells.Adv Exp Med Biol. 1983;163:247-57. doi: 10.1007/978-1-4757-5241-0_19. Adv Exp Med Biol. 1983. PMID: 6193688
-
The effect of leucovorin on the synthesis of methotrexate poly-gamma-glutamates in the MCF-7 human breast cancer cell line.Biochem Pharmacol. 1985 Aug 15;34(16):2897-903. doi: 10.1016/0006-2952(85)90013-9. Biochem Pharmacol. 1985. PMID: 2411271
-
Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr. 1987;(5):17-26. NCI Monogr. 1987. PMID: 2448654 Review.
-
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era.Stem Cells. 1996 Jan;14(1):29-32. doi: 10.1002/stem.140029. Stem Cells. 1996. PMID: 8820948 Review.
Cited by
-
In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes.Cancer Chemother Pharmacol. 1988;21(2):150-5. doi: 10.1007/BF00257363. Cancer Chemother Pharmacol. 1988. PMID: 2450691
-
Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.Cancer Chemother Pharmacol. 1988;21(2):145-9. doi: 10.1007/BF00257362. Cancer Chemother Pharmacol. 1988. PMID: 2450690
-
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.J Clin Invest. 1998 Jul 15;102(2):322-8. doi: 10.1172/JCI2676. J Clin Invest. 1998. PMID: 9664073 Free PMC article.
-
Reversal of methotrexate cytotoxicity to human bone marrow cells and leukemic K562 cells by leucovorin: methotrexate polyglutamates formation as a possible important factor.Jpn J Cancer Res. 1990 Nov;81(11):1162-7. doi: 10.1111/j.1349-7006.1990.tb02529.x. Jpn J Cancer Res. 1990. PMID: 1702414 Free PMC article.
-
Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells.Cancer Chemother Pharmacol. 1985;15(3):272-7. doi: 10.1007/BF00263900. Cancer Chemother Pharmacol. 1985. PMID: 2414022
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials